Strides Pharma Science Q1 FY26 – US 51% of Revenue, Profit +41%, But Promoter Pledge 50%: Growth Capsule or Side Effect?

1. At a Glance

Strides Pharma is that pharma company which always seems to be in a restructuring, acquisition, or USFDA tango. Q1 FY26 revenue at ₹1,120 Cr (+6% YoY) and PAT at ₹106 Cr (+41% YoY) look like a clean prescription. But the real kicker? Promoter holding is just 28%, with 50% of it pledged. Basically, the promoters are holding the syringe with one hand and pawning it with the other.

2. Introduction

Strides is the poster child of Indian pharma ambition—forever globetrotting, constantly restructuring, and eternally juggling acquisitions like a chemist juggling strips of paracetamol. Its footprint spans 100+ countries, with soft gelatin capsules as its claim to fame (think of it as the samosa of global dosage forms—everyone has tasted it).

But behind the glossy product launches, you’ll always find drama:

• USFDA withdrawals (Ranitidine, Losartan).
• Restructuring into newcos (OneSource CDMO).
• Debt flare-ups followed by debt diets.
• Promoter pledges that would make even Kingfisher Airlines blush.

The company promises 12–15% annual growth and a US sales target of $400m by FY28. Sounds nice, but with Strides, you always check the fine print—because half the time, it’s footnoted with “impairment, recall, or litigation.”

3. Business Model – WTF Do They Even Do?

• Pharma Generics (51% revenue from US): Niche formulations, licensing, partnerships. Ranked top-3 in 36 US products. Heavy focus on soft gels, capsules, and liquids.
• Branded Generics (Africa): “In Africa for Africa” strategy. Chronic therapies, women’s health, diabetes meds. Local brands like Renerve and Vitafer.
• Institutional Biz (17%): Supplying anti-retrovirals, malaria, TB, hepatitis drugs across Africa/Asia/LatAm. Funded markets = steady but low-margin.

In short: regulated market specialist, with the US now 50%+ revenue share—a dependence risk, but also the main growth driver.

4. Financials Overview

Commentary: QoQ dip in revenue, but PAT margin expanded to ~9.5%. The company is finally not bleeding cash. But with Strides, one clean quarter ≠ trend.

5. Valuation Discussion – Fair Value Range

1. P/E Method

• EPS TTM = ₹37
• Industry P/E ~33x
• Range = 18x–24x (given pledge/debt risk)
• Value = ₹660 – ₹890

2. EV/EBITDA Method

• EV